The public needs more protection from Big Pharma profiteering off of billions in taxpayer funded drug research.
Young adults living with diabetes are rationing insulin and dying when they age out of their parents’ insurance plans.
We want patients to buy prescriptions at reasonable prices, but we can’t rely on our northern neighbor forever.
Americans wanted to list drug price ads on TV. Big Pharma and a federal judge said no.
Sneaky pharma tactics are keeping lifesaving generic drugs out of reach for patients who need them most.
So many bipartisan drug pricing proposals, so little time.
The US pays two to three times more than other developed nations for prescription drugs.
The DOJ wants a jury trial for Mallinckrodt, the company at the heart of a 97,000 percent price spike for a gel mainly used to treat infant seizures.
Colorado is the first state to place a price cap on out-of-control insulin prices.
Spunky Maryland’s new drug pricing affordability board will be enacted July 1. We expect more reforms to come from states this year.
We need legislation to stop deals for delay and patent thickets, AbbVie’s monopolistic bread and butter.
Senators John Cornyn, a Texas Republican, and Richard Blumenthal, a Connecticut Democrat, proposed legislation this week to stop drug companies’ abusive patent tactics that block competition and crush taxpayers and patients.
In the first three months of 2019, PhRMA spent $10 million for 27 in-house lobbyists and 20 outside lobbyists. Swampy.
Welcome to the week in drug pricing news — no redactions.